The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit http://www.daiichisankyo.com
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.
This press release contains certain forward-looking statements about prasugrel for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with percutaneous coronary intervention and reflects Daiichi Sankyo's and Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that the product will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission and Daiichi Sankyo's filings with the Tokyo Stock Exchange. Daiichi Sankyo and Lilly undertake no duty to update forward-looking statements.
Efient(R)/Effient(R) is a registered trademark of Eli Lilly and Company.
Plavix(R) is a registered trademark of Sanofi-Aventis Corp.
P--LLY
(1) Smith PK, Despotis GJ, Goodnough LT, Levy, J, Poston, R, Short, M, et al. Mortality benefit with prasugrel in TRITON-TIMI 38 coronary artery bypass grafting (CABG) cohort: Risk adjusted retrospective data analysis. Abstract presented at: 2010 American Heart Association Scientific Sessions; November 2010; Chicago, IL.
(2) Smith PK, Despotis GJ, Goodnough LT, Levy, J, Poston, R, Short, M, et al. Mortality benefit with prasugrel in TRITON-TIMI 38 coronary artery bypass grafting (CABG) cohort: Risk adjusted retrospective data analysis. Study presented at: 2010 American Heart Association Scientific Sessions; November 2010; Chicago, IL.
(3) Data on File at Eli Lilly and Company. Coronary Artery Bypass Grafting Cardiovascular Death Data Table.
(4) European Medicines Agency. Summary of Product Characteristics.
(5 Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine. 2007:357(20);2001-2015.
(6) Wiviott S, Antman E and Braunwald. New Drugs and Technologies: Prasugrel. DOI: 10.1161 Circulation AHA.109.921502 p394-403.
(7) British Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics 2008. Updated 2008. Accessed November 4, 2010.
(8) American Heart Association. Heart Disease and Stroke Statistics - 2008 Update. Dallas, TX. American Heart Association. (Pg. 14).
(9) WebMD Medical Reference in Collaboration with the Cleveland Clinic. Heart Disease: Coronary Artery Disease. Accessed March 5, 2010.
(Logo: http://photos.prnewswire.com/prnh/200611... )
(Logo: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO )
CONTACT: Tammy Hull, Eli Lilly and Company, +1-317-651-9116 (office),+1-317-614-5132 (cell); Dr. Michaela Paudler-Debus, Daiichi Sankyo EuropeGmbH, +49-(0)89-78-08-685 (office), +49-(0)172-845-8974 (cell); ShigemichiKondo, Daiichi Sankyo (Tokyo), +81-3-6225-1126 (office)
